Clinical proteomics: A need to define the field and to begin to set adequate standards. - Wikidata - wikimedia - TriplyDB

Clinical proteomics: A need to define the field and to begin to set adequate standards.

Clinical proteomics: A need to define the field and to begin to set adequate standards.

http://www.wikidata.org/entity/Q40247421

about

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies Perspectives on systems biology applications in diabetic kidney disease Identifying novel biomarkers through data mining-a realistic scenario?Proteomics and metabolomics in renal transplantation-quo vadis?Current application of proteomics in biomarker discovery for inflammatory bowel disease Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy The application of mass-spectrometry-based protein biomarker discovery to theragnostics Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics.Discovery and validation of urinary biomarkers for prostate cancer Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments Classification-based comparison of pre-processing methods for interpretation of mass spectrometry generated clinical datasets.Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications.Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer Proteomic analysis of gliomas.Two-dimensional electrophoretic comparison of metastatic and non-metastatic human breast tumors using in vitro cultured epithelial cells derived from the cancer tissues.Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression.Integrated multi-level quality control for proteomic profiling studies using mass spectrometry.Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm.Approaching clinical proteomics: current state and future fields of application in fluid proteomics.Challenges for biomarker discovery in body fluids using SELDI-TOF-MS.Application of Proteomic Analysis to Renal Disease in the Clinic.Sources of Urinary Proteins and their Analysis by Urinary Proteomics for the Detection of Biomarkers of Disease High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine Applying proteomics to the diagnosis and treatment of ALS and related diseases.Addressing the challenge of defining valid proteomic biomarkers and classifiers.Discussion on common data analysis strategies used in MS-based proteomics.Cardiovascular proteomics: translational studies to develop novel biomarkers in heart failure and left ventricular remodeling.Strategy for degradomic-peptidomic analysis of human blood plasma Towards proteome standards: the use of absolute quantitation in high-throughput biomarker discovery.Enhanced information output from shotgun proteomics data by protein quantification and peptide quality control (PQPQ).Effect of storage temperature as a preanalytical variable on the lens crystallins protein quality for proteomic studies.Functional protease profiling for diagnosis of malignant disease.Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease.MALDI MS imaging as a tool for biomarker discovery: methodological challenges in a clinical setting.Prediction of the clinical outcome in invasive candidiasis patients based on molecular fingerprints of five anti-Candida antibodies in serum An automated plasma protein fractionation design: high-throughput perspectives for proteomic analysis.

P2860

Q24289435-71068322-0AA4-4842-B7B4-07C8FAA261A8 Q24604179-E5CC5131-B16D-42E9-B70A-C33FB209A1CF Q26823206-04F45689-C4FC-434A-9735-4F6DBAFE98EA Q26995754-711A8997-F398-4A54-9A56-489E782CF966 Q27024418-3A538051-3BB1-4BBA-AA32-1964404BCC0F Q28078755-B844F886-0995-4590-B4B7-AF6D762FF2FB Q28477629-C764882C-EDFE-474A-9CF5-77F9A8680D17 Q28478586-D09CCB94-5EC4-4870-816E-984959C7B1EA Q28748224-F48FA127-64A1-498C-BBC4-15DED365FB46 Q30430034-44E6CEB5-B434-4C43-A62D-A2B291797D57 Q30437141-C59482C0-F393-4F7B-8EEF-2681FACD5809 Q30438582-5BCD8897-EBCF-43FB-AEBC-1B65CD5462A0 Q30438814-4D90538F-6215-4464-BCD8-623A1DCAABEE Q30487959-8CC565D6-6CD2-4947-9D42-4CA4D0CF1FCB Q31148183-7B52FDD4-642F-4CDD-9EDB-AA3CEE961CD0 Q33304961-1B1362FA-0189-4554-9AC7-4E15BAA96B16 Q33306300-E64FADA7-5453-4526-92E8-B0E6DD390712 Q33309684-180335A3-5E51-4F65-BAC5-38DC48D8152E Q33328683-6956130F-84FE-4BB4-B18C-4BA3D5CECD72 Q33338626-26A0FA4D-A76A-46B2-83BB-1C4E04D52544 Q33389590-71D57FB0-9C22-4463-8265-0A56B74FEC59 Q33436829-3A179AE0-9B91-448A-8DCA-78DE2DE44A4D Q33467523-2887A544-482D-4B13-90C5-B5C76B6368EC Q33520447-C4F75224-8D94-4E24-9D4B-E62DE2BF0280 Q33575004-231EE801-8E97-4E1F-9745-33B10CF782C6 Q33597457-CFBE004C-0C31-42A1-970C-01C87AB86356 Q33610197-81E06E21-9236-495E-915B-04C5DBB7DC7A Q33719446-DE1B25F7-999B-45E7-ADF6-15B943FF7FBE Q33786157-86E7FD84-7598-4E80-BE56-8518D25E08F6 Q33795085-1208DB3F-7012-48CB-8DDD-82DD73DA8053 Q33797033-BC54BCF2-C41C-43B0-82FF-D81B370C9C15 Q33835867-306BB477-0A8F-4537-B322-5EDAC4C883A8 Q33912503-C297FFC5-4160-4205-AC5C-F94EF18D20C3 Q33953287-B13A416D-7E11-42A8-83DA-AA7A2C2E7057 Q33990546-FF6AC4C6-81FB-4322-858F-B25E32F912AE Q34116114-F006A143-22B7-4223-A4CD-DC08851EC214 Q34129628-F05496D3-478C-4CFF-A181-A3BBAFFBAFD4 Q34454885-F131B21F-C01A-4162-A72D-CA249C715479 Q34454950-4D7F50A1-49D8-4143-A959-FFBA8AABB037 Q34463818-C11AB83E-8369-4702-A756-D1BDA4E426A9

P2860

Clinical proteomics: A need to define the field and to begin to set adequate standards.

http://www.wikidata.org/entity/Q40247421

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Clinical proteomics: A need to define the field and to begin to set adequate standards.

@en

Clinical proteomics: A need to define the field and to begin to set adequate standards.

@en-gb

type

label

Clinical proteomics: A need to define the field and to begin to set adequate standards.

@en

Clinical proteomics: A need to define the field and to begin to set adequate standards.

@en-gb

prefLabel

Clinical proteomics: A need to define the field and to begin to set adequate standards.

@en

Clinical proteomics: A need to define the field and to begin to set adequate standards.

@en-gb

P1433

Q40247421-67C3BEDD-50F4-4B09-BE58-D8178002B58B

P1476

Q40247421-413FD9AD-62A7-478E-BD48-19326EDB40C6

P2093

Q40247421-01F60623-1746-4CC6-A782-3EBFBD5532C7

Q40247421-0A6097FF-0270-4853-B133-D500142CDD9D

Q40247421-183D1419-3543-4D16-8086-68EDF02C372E

Q40247421-3134A05B-9D55-4E6E-9CA2-C253CD5B13D8

Q40247421-33D99BE6-DB80-47DF-B649-B9CE10BF6798

Q40247421-70492EDF-6BA0-4046-8664-0D34904D256B

Q40247421-760246EA-8B27-4EE0-9FDC-A8030AA7DED1

Q40247421-82F800C4-2A35-43E6-AF5E-2C7BF169017B

Q40247421-A45D87BE-F475-40A7-9767-D4225656A75F

Q40247421-ACE2098A-969B-4719-94D3-5144B276D35F

P2860

Q40247421-F3413E75-32A7-492E-A0C9-DBEE48811B79

P304

Q40247421-39F4E31C-0E91-4EF7-BCC0-C0C047A19331

P31

Q40247421-999A351F-1C4C-45D0-BA64-BC4502285157

P356

Q40247421-243609E6-FB3E-4A7B-A7F8-07464CF5A6BF

P433

Q40247421-8EA76F21-93C9-4452-8426-841B6F7023BF

P478

Q40247421-F7715468-498C-405A-9B53-B9620529CB4D

P50

Q40247421-29CD49BB-FE83-4FB9-A569-58A61A3B186F

Q40247421-2D095BE5-5F56-413F-808F-B1EF4C01E183

Q40247421-569A6239-F678-49DB-966E-7CA970662EB5

Q40247421-844F2F09-C335-4B9D-B17B-483403C05CF8

Q40247421-8CBDC0D6-E15E-4329-907B-4CE835D1D4C7

Q40247421-BFEBD223-5B73-4F90-AA07-904C0166F2D5

Q40247421-D47061D4-4417-4846-A3CF-8A75B8316609

Q40247421-DD70D72C-C601-4C3D-AAA1-CC2B0715C3DD

Q40247421-F1ED8B29-7ED6-4448-A450-0E8EDAE4E915

Q40247421-F9A6D48D-EB78-4944-855A-ADB678956768

P577

Q40247421-F767BD51-4DA9-43F5-978F-202921B78C01

P5875

Q40247421-CB0C3A92-3C47-49CC-9F28-8F63E9CE59B6

P698

Q40247421-B7FD2329-3121-4849-BBF0-EE6F731326E2

P356

P1433

Proteomics - Clinical Applications

P1476

Clinical proteomics: A need to define the field and to begin to set adequate standards.

@en

P2093

Bruce A Julian

http://www.w3.org/2001/XMLSchema#string

Christian Neusuess

http://www.w3.org/2001/XMLSchema#string

Dan Theodorescu

http://www.w3.org/2001/XMLSchema#string

Danilo Fliser

http://www.w3.org/2001/XMLSchema#string

Denis Hochstrasser

http://www.w3.org/2001/XMLSchema#string

Eva M Weissinger

http://www.w3.org/2001/XMLSchema#string

Jan Novak

http://www.w3.org/2001/XMLSchema#string

Jennifer E Van Eyk

http://www.w3.org/2001/XMLSchema#string

Joachim Jankowski

http://www.w3.org/2001/XMLSchema#string

Jochen H H Ehrich

http://www.w3.org/2001/XMLSchema#string

P2860

An updated coronary risk profile. A statement for health professionals.

P304

148-156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PRCA.200600771

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Henning Hermjakob

Rosamonde Elizabeth Banks

Visith Thongboonkerd

Karlheinz Peter

Anna Dominiczak

Joost P Schanstra

P577

2007-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229671782

http://www.w3.org/2001/XMLSchema#string

P698

21136664

http://www.w3.org/2001/XMLSchema#string